Diana Watral

Diana is a trial lawyer who focuses on multidistrict litigations, products liability disputes, False Claims Act cases, contract disputes, and class actions, and her clients include some of the largest pharmaceutical and life science companies. Diana leads two multidistrict litigations for Eli Lilly related to insulin pricing and GLP-1 products liability claims, along with nationwide litigation for knock-off GLP-1 medicines. Diana recently led Allergan (AbbVie) to defeat a massive False Claims Act case at summary judgment; defeated class certification against consumers in insulin pricing litigation; obtained dismissal of an antitrust case claiming AbbVie created a “patent thicket” for its drug Humira, the highest-selling drug in history; served as trial counsel to a large pharmaceutical company in a confidential arbitration seeking to invalidate a patent licensing agreement, with all arbitrators ruling for Diana’s client; served as trial counsel to Flexus Biosciences, a Bristol-Myers Squibb subsidiary, in a $1 billion trade secret jury trial that resulted in a complete defense verdict; and successfully defended Abbott in a $1 billion False Claim Act jury trial. Crain’s Chicago Business recognized Diana among its 2025 “Notable Litigators and Trial Attorneys,” a list honoring those who “advocate for clients in complex disputes and influence legal developments nationwide.”

University of Chicago Law School, J.D., with Highest Honors, Graduated first in class, Order of the Coif, 2010; Georgetown University, B.A., Government, magna cum laude, with Honors, with Distinction, 2007.